drugset / Trial / NCT00127972
2NN & CHARM Long-Term Follow-up Study
Phase 4
Completed
763 enrolled
International Antiviral Therapy Evaluation Center
Boehringer Ingelheim · collab
RandomizedSingle-groupOpen-label
Summary
It is desirable to obtain extended follow up data on subjects who participated in the 2NN study and the CHARM study in order to see if the beneficial effect of using nevirapine continues up to 144 weeks of treatment.
Timeline
- Start
- 2004-02
- Primary completion
- —
- Completion
- 2007-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Efavirenz | Other / unclassified | — | — |
| Subject | Nevirapine | Small molecule | — | — |
| Subject | Trizivir | Unknown | — | — |
| Background | Lamivudine | Other / unclassified | — | — |
| Background | Stavudine | Other / unclassified | — | — |